ABIONYX PHARMA SA (ABNX.PA) Stock Price, Quote, News and Overview
EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR
ABNX.PA Quote, Performance and Key Statistics
EPA:ABNX (3/7/2025, 7:00:00 PM)
1.298
0 (-0.31%)
The current stock price of ABNX.PA is 1.298 EUR. In the past month the price increased by 8.89%. In the past year, price increased by 24.09%.
ABNX.PA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
| 1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
| AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
| 1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
| GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
| ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
| IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
| 1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
| 0QF.DE | MODERNA INC | N/A | 13.19B |
Related stock screener links
About ABNX.PA
Company Profile
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 60 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Company Info
ABIONYX PHARMA SA
Bat. D 33-43 Avenue Georges Pompidou
Balma OCCITANIE FR
Employees: 61
Company Website: https://www.abionyx.com/en/
Investor Relations: http://www.abionyx.com/en/investors/regulated-information
Phone: 33562249706
ABIONYX PHARMA SA / ABNX.PA FAQ
What is the stock price of ABIONYX PHARMA SA today?
The current stock price of ABNX.PA is 1.298 EUR. The price decreased by -0.31% in the last trading session.
What is the ticker symbol for ABIONYX PHARMA SA stock?
The exchange symbol of ABIONYX PHARMA SA is ABNX and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ABNX.PA stock listed?
ABNX.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for ABIONYX PHARMA SA stock?
7 analysts have analysed ABNX.PA and the average price target is 11.73 EUR. This implies a price increase of 803.7% is expected in the next year compared to the current price of 1.298. Check the ABIONYX PHARMA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABIONYX PHARMA SA worth?
ABIONYX PHARMA SA (ABNX.PA) has a market capitalization of 45.34M EUR. This makes ABNX.PA a Nano Cap stock.
How many employees does ABIONYX PHARMA SA have?
ABIONYX PHARMA SA (ABNX.PA) currently has 61 employees.
What are the support and resistance levels for ABIONYX PHARMA SA (ABNX.PA) stock?
ABIONYX PHARMA SA (ABNX.PA) has a support level at 1.28 and a resistance level at 1.35. Check the full technical report for a detailed analysis of ABNX.PA support and resistance levels.
Should I buy ABIONYX PHARMA SA (ABNX.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABNX.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABNX.PA, evaluating the profitability, health, valuation and growth aspects
- ABIONYX PHARMA SA (ABNX.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABIONYX PHARMA SA (ABNX.PA) Sales and EPS estimates to see what analysts future expectations are.
- ABIONYX PHARMA SA (ABNX.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABIONYX PHARMA SA (ABNX.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABIONYX PHARMA SA (ABNX.PA) Stock Chart to make your own analysis
- ABIONYX PHARMA SA (ABNX.PA) Latest news and press-releases to stay up to date.
Does ABIONYX PHARMA SA (ABNX.PA) stock pay dividends?
ABNX.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of ABIONYX PHARMA SA (ABNX.PA)?
ABIONYX PHARMA SA (ABNX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
ABNX.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 83.47% of all stocks.
ABNX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA. While ABNX.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ABNX.PA Financial Highlights
Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 23.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.72% | ||
| ROE | -35.54% | ||
| Debt/Equity | 0.25 |
ABNX.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ABNX.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.